Noul: First Korean AI Health Firm Joins Swiss Malaria Group
TL/DR –
On-device AI healthcare company Noul has announced that its European subsidiary, noul GmbH, has become an official member of the Swiss Malaria Group. This comes in recognition of Noul’s innovative malaria diagnostic solution, miLab™ MAL, and allows the company to participate in the decision-making process aimed at developing healthcare policies to eliminate global malaria. The miLab™ MAL has been highlighted as an innovative malaria diagnostic solution in Unitaid’s 2022 Annual Report and has shown superior sensitivity and specificity in diagnosing P. falciparum and P. vivax malaria in a clinical study involving 1,649 patients in Ethiopia and Ghana.
Noul Co. Ltd. Joins Anti-Malaria Network Swiss Malaria Group
Renowned AI healthcare firm, Noul Co. Ltd. (376930.KR), has announced that its European arm, noul GmbH, has been granted membership by the Swiss Malaria Group. This is a significant recognition of the company’s innovation in malaria diagnostic solutions and reinforces its global leadership in malaria diagnosis.
As an official member of the Swiss Malaria Group, Noul will now have a voice in decision-making processes focused on developing healthcare policies to eradicate global malaria. The company also plans to strengthen its global cooperation with other group members.
The company’s malaria diagnostic solution, miLab™ MAL, played a key role in securing this membership. Introduced as ‘an innovative product that will enter scale-up level’ in Unitaid’s 2022 Annual Report, miLab™ MAL is gaining international attention as a groundbreaking solution that surpasses the limitations of rapid diagnostic testing and manual microscopic diagnosis.
Results from a clinical study involving 1,649 patients in Ethiopia and Ghana, unveiled in October 2023 at the American Academy of Tropical Medicine and Hygiene (ASTMH), attested to the effectiveness of miLab™ MAL. The solution demonstrated remarkably higher sensitivity and specificity in diagnosing P. falciparum and P. vivax malaria as compared to field microscopy tests.
Dr. Taehwan Kim, Managing Director of noul GmbH, stressed that their innovative solution would be instrumental in the global fight against malaria. He expressed optimism about their enhanced presence in the market and strategic collaboration with other members of the Swiss Malaria Group.
The Swiss Malaria Group lauded Noul’s innovative diagnostic tools, noting their alignment with the group’s focus on modern solutions in combating malaria.
Visit Noul’s website for additional information.
Photo – Noul and SMG Logo
Logo – Noul logo
—
Read More Health & Wellness News ; US News